Yan Leyfman
Mar 31, 2025, 06:04
Yan Leyfman: Expanding Antibody Therapeutics with TCR Mimicry
Yan Leyfman, Co-founder and Executive Director of MedNews Week, shared a post on LinkedIn:
“Expanding Antibody Therapeutics with TCR Mimicry.
Monoclonal antibody therapies have revolutionized treatment, but their reach is limited to extracellular targets. TCR mimetic (TCRm) antibodies overcome this by recognizing peptide-HLA (pHLA) complexes, unlocking a vast pool of intracellular-derived targets with greater specificity and affinity.
Key Highlights:
- TCRm antibodies extend antibody-based targeting beyond surface proteins
- Comprehensive pipeline integrates mass spectrometry, bioinformatics and cryo-EM
- TCRm CAR T cells demonstrate potent antitumor activity across multiple HLA alleles
This approach could pave the way for next-generation immunotherapies, expanding the potential of antibody-based treatments.”
Authors: Robert Salzler, David J. DiLillo, Kei Saotome, Kevin Bray, Katja Mohrs, Haun Hwang, Kamil J. Cygan, Darshit Shah
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 1, 2025, 12:16
Apr 1, 2025, 12:13
Apr 1, 2025, 12:07
Apr 1, 2025, 11:53
Apr 1, 2025, 11:51
Apr 1, 2025, 11:42